Avadel Pharmaceuticals plc announced that it has appointed Jordan Dubow as Chief Medical Officer. Dr. Dubow brings extensive experience leading clinical development programs in sleep and neurological disorders to Avadel, where he will lead the development of FT218 for the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. Prior to joining Avadel, Dr. Dubow served as Vice President, CNS Therapeutic Strategy with Esteve.